High efficacy of HPV 16/18 AS04-adjuvanted vaccine shown against CIN2+ associated with HPV-16/18 and non-vaccine oncogenic HPV types

Evidence-Based Medicine

Volumn 15, Issue 1, 2010, Pages 7-8

  Rambout, Lisa ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS A VACCINE; WART VIRUS VACCINE;

CANCER STAGING; DRUG EFFICACY; HEPATITIS A; HUMAN; NONHUMAN; NOTE; OUTCOME ASSESSMENT; PUBLIC HEALTH PROBLEM; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; UTERINE CERVIX CARCINOMA IN SITU; WART VIRUS;

EID: 77249087633     PISSN: 13565524     EISSN: 14736810     Source Type: Journal    
DOI: 10.1136/ebm1006     Document Type: Note

References (4)

1. Baseman JG, Koutsky LA. The epidemiology of human papillomavirus infections. J Clin Virol 2005;32(Suppl 1): S16-24.
2. World Health Organization. Initiative for vaccine research. Geneva: WHO 2009. http://www.who.int/vaccine-research/diseases/hpv/en/ (accessed 28 December 2009).
3. Rambout L, Hopkins L, Hutton B, et al. Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials. CMAJ 2007;177:469-79.
4. Pratt D, Goldenthal K, Geber A. Preventive human papillomavirus (HPV) vaccines: regulatory briefi ng document on endpoints. Vaccines and Related Biological Products Advisory Committee meeting, 28-29 November 2001, Bethesda, MD. http://www.fda.gov/ohrms/dockets/ac/01/briefi ng/3805b1-01.htm (accessed 28 December 2009).